Compare Abbott Laboratories (ABT) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.27. The key difference: Abbott Laboratories pays a 2.63% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and Abbott Laboratories is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| ABT | YINN | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $136.62 | $56.62 |
52-Week Low | $82.57 | $21.45 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
YINN (Direxion Daily FTSE China Bull 3x ETF) trades at $23.30, up 5.53% with a bearish technical signal from moving averages. The ETF faces structural risks from its leveraged exposure to Chinese equities, though recent sentiment shows some improvement as China's tech sector benefits from AI investments and export growth. Key support sits at $22-23 with resistance at $24.
Outlook remains cautious due to YINN's leveraged structure and China's regulatory environment. While AI-driven growth and index rebalancing may provide short-term catalysts, long-term risks include geopolitical tensions and valuation concerns. Investors should weigh the ETF's daily reset mechanism against China's economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
